Aerovate Therapeutics, Inc.
AVTE
$0.06
Change (1 day)
$32.42
Year High
$1.25
Year Low
Categories
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics, Inc. (AVTE) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -22,816,000 | 17.96 M | 127.42 M | 124.23 M | |
| 2022 | -21,307,000 | 8.56 M | 135.3 M | 131.5 M | |
| 2021 | -53,623,000 | 2.95 M | 175.36 M | 174.33 M | |
| 2020 | -4,573,000 | 18.06 M | 4.72 M | 4.68 M | |
| 2019 | -1,014,000 | 7.16 M | 3.51 M | 3.51 M |